Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the late 1960s Miles Vaughan Williams, a member of the staff in the Oxford Department of Pharmacology and Fellow of Hertford College (1955-85), introduced a novel classification of drugs used to treat cardiac arrhythmias. This scheme has been very widely used around the world and has led to the development of new drugs that have saved countless lives. Our understanding of the control of cardiac rhythm has developed in that time and a group of cardiovascular scientists from Oxford, Cambridge and Beijing led by Associate Professor Ming Lei decided that the time was ripe to modernise the classification and to celebrate the centenary of the birth of Vaughan Williams.

Together they have now published a comprehensive modern classification, based upon the original version, in the leading journal ‘Circulation’.

Findings over the past 5 decades from studies of different molecular drug targets, their mechanisms of action, and consequent clinical effects have led to the need to revise the classification. The modernised Oxford classification augments Vaughan Williams’s original framework covering the actions of sodium, potassium and calcium ions and the effects on these of the nervous system (Class I-IV). Novel categories now relate to altered heart rates (Class 0), mechanical stretch (Class V); intercellular electrical communication (Class IV) and longer term structural change (Class VII). The scheme then draws attention to multiple drug targets and actions and possible adverse, even pro-arrhythmic, effects.

This clarified classification of both the actions and therapeutic applications of both established drugs and novel drugs under investigation will improve current and future treatment of cardiac arrhythmias. It will encourage a rational clinical use of existing available anti-arrhythmic drugs in relationship to their particular mechanisms of action. It will aid identification and development of novel drugs relating their future clinical applications to their molecular mechanisms of action.  

The classification commemorates and advances the landmark contributions of Miles Vaughan Williams (https://en.wikipedia.org/wiki/Miles_Vaughan_Williams) to the physiology of the heart that began this quest nearly half a century ago on this centenary of his birth. It is likely that the new classification will have an enduring impact on cardiological medicine.

See the text of the paper here:

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.035455

https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035455.

Similar stories

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.

New blood test from DPAG cardiac researchers could save lives of heart attack victims

Researchers from the Herring group have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

Professor Barbara Casadei awarded 2022 Nylin Medal

The Swedish Society of Medicine has awarded the 2022 Nylin Medal to Professor Barbara Casadei, part of the Oxford BHF CRE leadership team.

Joaquim Vieira recognised in national image competition

DPAG BHF Intermediate Research Fellow Dr Joaquim Vieira has been shortlisted for the British Heart Foundation’s annual ‘Reflections of Research’ image competition.

Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies

RDM researchers tested the method in COVID-19 patients, to find that the results predicted in-hospital mortality.

BHF Senior Fellowship renewal for Duncan Sparrow could pave the way to revealing unknown causes of heart defects in babies

Congratulations are in order for Associate Professor Duncan Sparrow, who has been awarded a renewal of his British Heart Foundation Senior Basic Science Research Fellowship. The award will fund crucial investigations into little understood environmental risk factors of congenital heart disease, and could one day lead to new therapeutic strategies.